Colorectal Cancer Pipeline 2016 Global Market Review Covering 227 Companies
PUNE, India, August 10, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Colorectal Cancer - Pipeline Review, H1 2016" market research report to its store providing an overview and comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects.
Colorectal Cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 27, 100, 97, 7, 135, 36 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 9, 8, 21 and 3 molecules, respectively. Complete report on H1 2016 pipeline review of Colorectal Cancer with 130 market data tables and 17 figures, spread across 1564 pages is available at http://www.rnrmarketresearch.com/colorectal-cancer-pipeline-review-h1-2016-market-report.html.
Companies discussed in this Colorectal Cancer Pipeline Review, H1 2016 report include 2cureX ApS, 3-V Biosciences, Inc., 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International, Inc., Actinium Pharmaceuticals, Inc., Adamed Sp. z o.o., Advaxis, Inc., Advenchen Laboratories, LLC, Alchemia Limited, Allinky Biopharma, Amal Therapeutics SA, Amgen Inc., Antibe Therapeutics, Inc., Apac Biotech Pvt Ltd, Apexigen, Inc., Aphios Corporation, Aposense Ltd., Arisaph Pharmaceuticals, Inc., ArQule, Inc., Array BioPharma Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, ATLAB Pharma SAS, AVEO Pharmaceuticals, Inc., Basilea Pharmaceutica AG, Bavarian Nordic A/S, Bayer AG, BeiGene, Ltd., Biocon Limited, Bionomics Limited, Bionovis SA, Biotecnol, Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Burzynski Research Institute, Inc., Calithera Biosciences, Inc., Carna Biosciences, Inc., Cascadian Therapeutics Inc, CCRP Therapeutics GmbH, Celator Pharmaceuticals, Inc., Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Celltrion, Inc., Chiome Bioscience, Inc., Chipscreen Biosciences Ltd, Cipla Ltd., Cleave Biosciences, Cleveland BioLabs, Inc., Clonz Biotech Private Limited, Coare Biotechnology, Inc., Coherus BioSciences, Inc., Cornerstone Pharmaceuticals, Inc., Corvus Pharmaceuticals, Inc., Critical Outcome Technologies Inc., CritiTech, Inc., CrystalGenomics, Inc., Cytune Pharma SAS, Daiichi Sankyo Company, Limited, DanDrit Biotech A/S, Deciphera Pharmaceuticals, LLC, Delcath Systems, Inc., Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L., Double Bond Pharmaceutical International AB, Dr. Reddy's Laboratories Limited, EirGenix Inc., Eisai Co., Ltd., Eli Lilly and Company, Endor Nanotechnologies SL, enGene, Inc, EnGeneIC Ltd, Ensol Biosciences Inc., EntreChem, S.L., Enzo Biochem, Inc., Etubics Corporation, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Fusion Antibodies Limited, Gene Techno Science Co., Ltd., Genentech, Inc., Genor BioPharma Co., Ltd., Genoscience Pharma, Genzyme Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Glycotope GmbH, Golden Biotechnology Corp., Green Cross Corporation, Hadasit Medical Research Services & Development Ltd, Hanmi Pharmaceuticals, Co. Ltd., Heat Biologics, Inc., Hemispherx Biopharma, Inc., Hetero Drugs Limited, Hutchison MediPharma Limited, iDD biotech SAS, Ideaya Biosciences Inc, Ignyta, Inc., Immatics Biotechnologies GmbH, Immodulon Therapeutics Ltd., ImmuneXcite, Inc., Immunomedics, Inc., Immunovative Therapies, Ltd., Incanthera Ltd., Incyte Corporation, Innovent Biologics, Inc., Inovio Pharmaceuticals, Inc., Interprotein Corporation, Ionis Pharmaceuticals, Inc., Isofol Medical AB, ISU ABXIS Co.,Ltd., Jeil Pharmaceutical Co., Ltd., JHL Biotech, Inc., Jiangsu Hengrui Medicine Co., Ltd., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Kancera AB, Karyopharm Therapeutics, Inc., Kolltan Pharmaceuticals, Inc., Kura Oncology, Inc., Laboratorio ELEA S.A.C.I.F. y A., Lee's Pharmaceutical Holdings Limited, Loxo Oncology, Inc., Mabion SA, Mabtech Limited, mAbxience S.A., MacroGenics, Inc., MediaPharma s.r.l., MedImmune, LLC, Medinet Co., Ltd., Medivation, Inc., Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Merus B.V., Mirna Therapeutics, Inc., MolMed S.p.A., Mologen AG, Momenta Pharmaceuticals, Inc., Morphotek, Inc., Multimmune GmbH, Mycenax Biotech Inc., Natco Pharma Limited, NatureWise Biotech & Medicals Corporation, Nektar Therapeutics, Neovacs SA and more.
Order a copy of Colorectal Cancer - Pipeline Review, H1 2016 market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=655390 .
Explore more reports on Cancer Therapeutics .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed
Share this article